Onset and Progression of Behavioral and Molecular Phenotypes in a Novel Congenic R6/2 Line Exhibiting Intergenerational CAG Repeat Stability by Cowin, Randi-Michelle et al.
Onset and Progression of Behavioral and Molecular
Phenotypes in a Novel Congenic R6/2 Line Exhibiting
Intergenerational CAG Repeat Stability
Randi-Michelle Cowin
1, Nghiem Bui
1, Deanna Graham
1, Jennie R. Green
1, Stephan Grueninger
2, Lisa A.
Yuva-Paylor
1, Arsalan U. Syed
1, Andreas Weiss
2, Richard Paylor
1,3*
1Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, United States of America, 2Novartis Institutes for BioMedical Research,
Neuroscience Discovery, Basel, Switzerland, 3Department of Neuroscience, Baylor College of Medicine, Houston, Texas, United States of America
Abstract
In the present study we report on the use of speed congenics to generate a C57BL/6J congenic line of HD-model R6/2 mice
carrying 110 CAG repeats, which uniquely exhibits minimal intergenerational instability. We also report the first
identification of the R6/2 transgene insertion site. The relatively stable line of 110 CAG R6/2 mice was characterized for the
onset of behavioral impairments in motor, cognitive and psychiatric-related phenotypes as well as the progression of
disease-related impairments from 4 to 10 weeks of age. 110Q mice exhibited many of the phenotypes commonly associated
with the R6/2 model including reduced activity and impairments in rotarod performance. The onset of many of the
phenotypes occurred around 6 weeks and was progressive across age. In addition, some phenotypes were observed in mice
as early as 4 weeks of age. The present study also reports the onset and progression of changes in several molecular
phenotypes in the novel R6/2 mice and the association of these changes with behavioral symptom onset and progression.
Data from TR-FRET suggest an association of mutant protein state changes (soluble versus aggregated) in disease onset and
progression.
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Introduction
Huntington’s disease (HD) is a progressive neurodegenerative
disorder characterized by a variety of motor, cognitive, and
psychiatric symptoms. Caused by an expansion of the polygluta-
mine (Q) tract in the human Huntington’s disease gene, HTT,H D
occurs in patients with greater than 35 CAG repeats, while
expansions in the range of 80–100Q results in the juvenile form of
the disease [1,2,3,4]. The R6/2 line is one of the most frequently
studied mouse models of HD due to the relatively early onset and
severity of disease phenotypes [5]. To date most of the R6/2
studies have used transgenic mice from a mixed CBA.C57BL/6
(CBA.B6) genetic background. It is well known that genetic
background can have dramatic effects on a number of behavioral
phenotypes [6,7,8], therefore, it is also important to create and
study R6/2 mice on a more controlled genetic background.
Recently, Menalled et al. [6] reported the first results of the
behavioral phenotypes of R6/2 mice on a congenic C57BL/6J
(B6) genetic background; however, the transgenic mice from this
study carried approximately 260 CAG repeats, a CAG repeat
length that is considerably longer than is commonly seen in human
patients. In addition, mice carrying CAG repeat numbers in this
range or larger have recently been shown to exhibit variable
phenotypes [6,9,10]. The goal of the present study was to develop
a congenic line of R6/2 transgenic mice that contained a CAG
repeat length in a range that is more comparable to other mouse
models of HD (e.g. R6/1, N171-82Q, YAC72, YAC128 and
many of the knock-in lines) [5,11,12,13,14,15,16,17]. Using speed
congenics we generated a line of R6/2 transgenic mice that
express 110–120 CAG on a pure B6 genetic background and
characterized the onset and progression of a number of behavioral
phenotypes in this new B6 110Q R6/2 line. In addition, we
examined a number of molecular markers including mRNA
expression and newly developed FRET-based protein assessments
of both soluble and aggregated HTT protein [18]. Although a
potentially important and revealing aspect of diseased progression
and characterization, there have been no previous studies
reporting a formal investigation of the molecular changes that
occur concurrently with decline in behavior phenotypes of in R6/
2 mice.
The findings from the present study indicate that behavioral
phenotypes in this B6 110Q R6/2 line emerge and progress from
4 to 10 weeks of age and that these changes are associated with
concurrent changes in soluble and aggregated protein levels, but
not transgene transcript expression. In addition, quantification of
CAG repeat length indicates that this particular line of R6/2 mice
has a minimal level of intergenerational instability. Finally,
because future studies from our lab will be directed at using this
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28409new line to identify potential modifiers of HD, we report our
characterization of the original R6/2 insertion site [5] on mouse
chromosome 4. To our knowledge, this is the first study to identify
the location of the R6/2 transgene. We believe the 110Q R6/2
line described in the present study offers a number of features that
will be useful to investigators interested in using R6/2 mice to
better understand HD.
Results
CAG Repeat Stability
The R6/2 line of mice was created by a random insertion of a
construct containing the first exon of the human HTT gene, driven
by the endogenous promoter [5]. While originally generated
expressing approximately 150 CAG repeats [5], the CBA.B6 R6/2
mice obtained for the current study from Jackson Laboratories,
descendant from the mouse line originally characterized by
Mangiarini et al. [5], carried a contracted repeat length of
approximately 110 polyglutamine (Q) (Table 1).
In order to efficiently create a pure and congenic B6 R6/2 line
we employed a speed-congenics breeding scheme. Briefly, a panel
of 96 SSLP (single nucleotide length polymorphism) markers was
selected throughout the genome for PCR genotyping. In each
generation, male progeny were genotyped both for the presence of
the exon 1 transgene as well as for the allele type (CBA or C57B/
6J) for each of the 96 makers selected. Mice with the highest
percentage of B6 alleles were bred preferentially. Although DNA
from original mice received from Jackson Laboratories, Inc. were
not genotyped with the SSLP panel, we found that after the first
backcross to pure B6, 110Q mice in our colony ranged from 39%–
61% homozygous B6 for the selected markers. The selective
breeding technique resulted in a line of congenic R6/2 mice as
early as 4 generations (95%–100% homozygous C57BL/6) with
the entire population 99%–100% congenic (as defined by the
SSLP marker panel) within 7 generations (Figure 1).
Early in the process of backcrossing the 110Q R6/2 mice,
however, it became apparent that our line of 110Q R6/2 mice
exhibited a distinct trait. Namely, the intergenerational repeat
expansions commonly observed in R6/2 mice [6,9,10,19] did not
occur with the expected progressive expansion rate in our
congenic line (Table 1). In fact, the variability of repeat length
within a generation appeared to decrease with successive
generations. We also measured the repeat length across multiple
generations of breeding in two other R6/2 lines bred within our
colony at Baylor College of Medicine as a comparison with other
B6 congenic R62 lines with longer CAG repeats [6,9,10]. We
found that in the other lines of R6/2 mice bred within our colony,
CAG repeat lengths readily expanded across 6–8 generations
(Table 1). Therefore, the lack of intergenerational expansion
observed in this new B6 110Q R6/2 line is not the result of
something unique to our breeding program.
Characterization of the Transgene Insertion Site
During the creation of the congenic 110Q line, 1 of the 96 SSLP
markers chosen for the speed congenics panel was found to be
extremely resistant to homologous recombination and remained
heterozygous for many generations after successfully obtaining
congenicity in the other 95 markers. We interpreted the difficulty
of recombining this SSLP marker to the B6 allele as suggesting
that the random and unnamed insertion site of the R6/2 transgene
was near the chromosomal location of the marker D4Mit303
located on mouse chromosome 4: 97876919–97877039 (NCBI
Build 37.2). To confirm that the transgene had integrated near the
D4Mit303, PCR-based GenomeWalker technology was used to
isolate genomic sequences flanking the transgene insertion site.
Sequence analysis of the junction indentified the insertion site as
within an intron of the predicted gene Gm12695 on chromosome
4. Relative to the forward strand, the exact insertion site is 39 of
base-pair 4: 96409480 (assembly NCBI 37/mus musuculus 9)
(Figure 2). Because this line of mice is a direct descendant of the
Table 1. Average repeat length of three R6/2 lines showing intergenerational stability or instability and the minimum and
maximum repeat lengths identified in each generation.
110Q Line X Line Y
Generation Mean ± SEM Min Max Mean ± SEM Min Max Mean ± SEM Min Max
Received 108.960.59 101 118 249.762.60 235 260 286.861.90 278 291
F1 110.660.70 101 119 260.361.60 231 275 291.361.60 278 304
N2 110.860.20 109 114 249.860.70 246 254 302.361.50 272 329
N3 111.260.20 109 113 252.161.60 231 263 309.261.50 287 324
N4 112.760.80 110 116 255.167.20 183 279 313.161.90 256 326
N5 110.960.30 108 112 281.061.80 265 295 333.663.10 304 469
N6 109.860.40 108 112 336.764.20 304 398
N7 109.960.20 107 112 344.164.40 315 359
N8 110.860.30 108 114
N9 111.260.24 109 114
N10 112.360.15 109 115
N11 112.560.25 110 116
N12 112.460.50 101 115
N13 114.660.50 112 117
Average change
per generation
.438 CAG 6.260 CAG 8.186 CAG
doi:10.1371/journal.pone.0028409.t001
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chromosomal location as the insertion site would be confirmed in
150Q mice.
Behavioral Characterization
In order to identify the age of onset and pattern of disease
progression in the minimally unstable and congenic 110Q R6/2
mice, behavioral analysis was performed. Male and female 4, 6, 8,
and 10 week oldR6/2and wild-type micewere tested in a variety of
tests to assay for a number of domains of CNS function including
motor coordination, exploratory activity, anxiety-related responses,
sensorimotor gating, and learning and memory.
R6/2 mice show reduced activity and exploration in the
open field assay at an early age. R6/2 and wild-type mice
were tested in the open field assay to assess disease onset and
progression in activity and exploration. Overall, transgenic mice had
significantly lower activity measures of total distance than wild-type
littermates [F(1,203)=98.757, p,0.001]. However, a significant
genotype6age interaction was found [F(1,203)=16.256, p,0.001]
indicating that the genotype effect was age dependent. Specifically,
transgenic mice explored lessthanwildtype animals at 8 and 10 weeks
of age. Additionally, transgenic 110Q mice exhibited similar levels of
exploration at 4 and 6 weeks of age, but at 8 and 10 weeks of age the
activity of transgenic mice was significantly reduced (p-values,0.001)
(Figure 3a). Within wildtype mice, activity was significantly increased
in 8 and 10 week old mice relative to 4 and 6 week old wildtypes (p-
values#0.008).
Similar to the exploratory activity, rearing behavior in the open-
field was also decreased overall in R6/2 transgenic mice compared
to wild-type littermates [F(1,203)=176.273, p,0.001], but this
difference was age dependent as indicated by a genotype6age
interaction [F(1,203)=29.819, p,0.001]. Simple effects analysis
revealed that transgenic mice rear significantly less than controls at
6, 8 and 10 weeks of age (p-values#0.001), but not at 4 weeks.
Changes across age were also identified in both genotypes.
Specifically, transgenic mice reared less at 8 and 10 weeks than
mice at 4 and 6 weeks of age (p-values#0.001). In wildtype mice,
Figure 2. Location of the insertion site of the R6/2 transgene. The insertion site localized to a position on mouse chromosome 4 in an intron
of predicted gene GM12695. The junction of the 59 insertion site was sequenced through approximately 1400 bp of the transgene. The represented
structure of the R6/2 insertion (for areas not sequenced) is based on the report by Mangiarini et al. (1996). Underlined sequences represent the
primers used to amplify across the junction. Sequence given in black represents chromosome 4. Sequence given in grey represents transgene.
doi:10.1371/journal.pone.0028409.g002
Figure 1. Congenicity across multiple generations of back-
crossing R6/2 mice to C57BL/6J. Average percentage of homozy-
gous B6 markers based on the 96-marker panel. Average percent B6
homozygosity was less than 50% after the first backcross but reached
congenicity of 95% by the N4 generation.
doi:10.1371/journal.pone.0028409.g001
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(p-values#0.022) (Figure 3b).
Anxiety measures in the open field are present in
transgenic animals at specific ages. To assess anxiety-like
behavior in the open field, the distance traveled in the center of the
open field is divided by the total distance traveled in the entire field
(center:total distance ratio). A lower ratio is indicative of an
increase in anxiety-like behavior [20,21]. Analysis revealed an
overall main effect of genotype [F(1,203)=12.566, p,0.001] with
transgenic mice having a lower ratio relative to wildtype mice
(Figure 3c). Unlike other measures of the open field assay, the
genotype6age interaction was not significant (p=0.135).
Onset of motor impairments on the rotarod assay occurs
early in 110Q mice. 110Q transgenic mice showed motor
impairments in the rotarod assay compared to wildtype mice
[F(1,204)=122.994, p,0.001], but this difference was age
dependent. Simple effects analysis of the significant
genotype6age interaction [F(3,204)=7.002, p,0.001] showed
that as early as 6 weeks of age R6/2 transgenics exhibited
impairments in the rotarod assay. A significant decrease in the
latency to fall from the rod was observed at 6, 8 and 10 weeks of
age in R6/2 mice relative to wildtype mice (p-values,0.001)
(Figure 4a). As the mice aged, motor impairments in the R6/2
mice progressed with significant differences between 6 and 10
weeks of age (i.e. 4 weeks.6 weeks.10 weeks; 8 weeks=6, 10
weeks) (p=0.039, Table 2). Performance across age in wildtype
mice was largely stable across age with a significant increase in
performance only occurring between mice at 4 weeks and mice at
8 weeks of age (p=0.018).
R6/2 mice show significant weight loss. 110Q mutant
mice were found to weigh significantly less than control mice
[F(1,204)=161.31, p,0.001] (Figure 4b). A genotype6age
interaction was found [F(1,204)=161.310, p,0.001].
Specifically, weight differences were apparent by 6 weeks and at
later ages of the transgenic mice (p-values,0.001). Although
transgenic mice gained weight from 4 to 6 weeks of age (p,0.001),
110Q mice did not continue to gain weight normally after 6 weeks
(p-values$0.215). In contrast, wildtype mice gained weight at
every age (p-values#0.035). Additionally, a genotype6gender
interaction was identified [F(1,204)=10.586, p=0.001]. Follow-
up analyses revealed gender differences in both genotypes (p-
values,0.001) with females weighing significantly less than males.
Gender differences in body weight are not surprising and not likely
to be contributing disproportionately to the overall effect of
genotype observed. Furthermore, genotype differences were
identified for both genders (p-values,0.001) and both male and
female transgenic mice were again shown to weigh significantly
less than controls. Although there was a significant gender
difference in both genotypes, the significant interaction resulted
from a greater mean difference between genders in wildtype
relative to R6/2 mice.
Transgenic mice show reduced startle and, at later ages,
a loss of prepulse inhibition (PPI). Overall, the acoustic
startle response was reduced in R6/2 mice relative to wildtypes
[F(1,203)=72.451, p,0.001], but this difference was dependent
on age and gender as revealed by a genotype6age6gender three-
way interaction [F(1,203)=3.273, p=0.022]. Both male and
female transgenic mice exhibited impairments in the startle
response amplitude at 4 weeks old (males: p=0.012; females:
p=0.025) (Figure 5a–b). Female startle responses increased after 4
weeks of age to wildtype levels (p-values$0.135, Figure 5a) and
although the startle response in male transgenics also increased
(from 6 to 8 weeks, p,0.001) they remained significantly below
wildtype levels (p-values,0.001, Figure 5b). While no main effects
of genotype, age or gender were identified when average PPI
values were analyzed, genotype6age [F(3,203)=4.569, p=0.004]
and genotype6gender interactions [F(1,203)=6.902, p=0.009]
were found. Further analysis revealed genotype differences only in
Figure 3. Behavioral responses of B6 R6/2 transgenic and
wildtype mice across 4 ages in the open-field test. (A)
Exploratory activity as measured by total distance traveled in an
open-field. (B) Rearing behavior as measured by vertical activity (beam
interruptions). In both A and B,‘ a’ represents that R6/2 mice are
significantly less active than wildtype littermates at 6, 8 and 10 weeks of
age. ‘b’ represents that 8 and 10 week old R6/2 mice are less active than
4 and 6 week old R6/2 mice. Wildtype mice increase in activity from 6 to
8 weeks of age. (C) Anxiety-like responses as measured by the
center:total distance ratio. ‘*’ represents that overall B6 R6/2 transgenic
mice spend less of their exploration in the center of the open-field
relative to wildtype mice. All p-values#0.022 by three-way ANOVA and
simple effects analysis.
doi:10.1371/journal.pone.0028409.g003
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existed only in male mice (p,0.001) (Figure 5d).
HD-model mice have impaired performance in the
passive avoidance test. To investigate learning and memory
in R6/2 mice we utilized the striatal-based passive-avoidance
learning task [22,23]. Many learning and memory assays require
an animal to respond with movement or otherwise perform a task.
Due to the motor phenotypes observed in the 110Q R6/2 mice,
we reasoned that the passive avoidance task would allow us to
identify any motor confounds. Specifically, we believed that if
motor impairments interfered with the task they would be easily
identified because the mice would take longer to enter the dark
thus resulting in a ‘‘better’’ score. For example, if an animal has
associated the dark chamber with a foot shock, the animal will
avoid the dark chamber, remaining for a longer time in the
brightly lit chamber. The longer latency to enter the dark is
interpreted as an indication of learning/memory. The higher the
latency, the more compelling the data suggesting the animal has
learned to associate the dark chamber and foot shock. However, if
an animal suffers from severe motor impairments, it may take
longer to enter the dark chamber due to the physical limitations
thus resulting in a falsely positive learning score for latency to enter
the dark. Based on the motor impairments exhibited in R6/2
mice, we would expect the latency to enter the dark during a
passive avoidance test to be increased partially due to motor/
activity impairments. Therefore, if the R6/2 mice still have lower
escape latencies relative to wildtype mice during the memory test
then this difference cannot be attributed to impaired activity.
To look at the performance of naı ¨ve mice we analyzed the
latency to enter the dark on training day 1 of the assay. Naı ¨ve
transgenic mice took significantly longer to enter the dark chamber
than wildtype mice [Wt: 10.4660.640, Tg: 17.6461.143;
F(1,192)=26.672, p,0.001], indicating that indeed they have
reduced activity in the passive avoidance assay as was observed in
the open field. Data from testing days 2 and 3 revealed an overall
effect of genotype [F(1,192)=31.156, p,0.001] and a genotype6
age interaction [F(3,192)=3.666, p=0.013]. Further analysis
showed that at 4 weeks of age, the latency to enter the dark during
test days 2 and 3 in transgenic animals was similar to that of
wildtype mice (Wt: 106.44615.07, Tg: 111.12616.93; p=0.801),
but by 6 weeks performance of transgenic animals was impaired
and the mutant mice entered the dark on days 2 and 3 more
quickly than wildtype littermates (Wt: 169.91619.896, Tg:
108.04612.817; p,0.001). This impaired performance continued
at 8 and 10 weeks of age (8 weeks Wt: 196.0624.861, Tg:
101.72612.73, p=0.018; 10 weeks Wt: 200.7620.328, Tg:
100.09617.715, p,0.001) (Figure 6a) but no changes across age
were observed in transgenic animals although wildtype mice
performed differently at specific ages (Table 2).
In a separate analysis, we asked the question: does the
performance of wildtype and transgenic mice improve across days
(i.e. are the mice learning)? We found that on day 2 of training
both wildtype and transgenic animals exhibited increased latencies
to enter the dark compared to day 1 (p-values,0.001) (Figure 6b).
In addition, the performance of both genotypes improved again,
between days 2 and 3 (p-values,0.001) indicating that although
the R6/2 mice are impaired relative to wildtype mice, their
performance improves.
Transgene Expression Levels
Molecular phenotypes have been shown to be associated with
disease progression in other HD mouse models [24,25] and, to the
best of our knowledge, no studies have been done in which the
molecular phenotypes in the R6/2 model have been studied in
association with disease onset or progression. Therefore, in order
to more fully characterize the congenic R6/2 mice, we
investigated the molecular features of the 110Q transgenic mice.
We reasoned that insights into disease onset and progression in the
110Q mice might be gained by understanding the molecular
changes that occur in concert with motor and cognitive symptoms.
Transgene transcript expression levels do not change
with age or disease state in 110Q mice. mRNA from 110Q
mice was analyzed at 4, 6, 8 and 10 weeks of age to determine
whether changes in gene expression change over time with disease
progression. No changes were observed between samples from
R6/2 mice at 4, 6, 8 or 10 weeks of age for either transgene (HTT)
or homologous endogenous gene (Hdh) expression (p$0.205,
Table 3).
Soluble transgene protein levels decrease and aggregate
transgene protein levels increase with age and disease
progression. Protein levels from 4, 6, 8 and 10 week old 110Q
R6/2 mice showed a pattern of protein state changes in which
soluble protein levels decreased with disease onset and progression
Figure 4. Motor coordination and skill learning on the rotarod
and body weights in R6/2 mice across 4 ages. (A) Latency to fall
from the rotarod. (B) Bodyweight measurements from 4 to 10 weeks of
age. In both A and B,‘ a’ represents that R6/2 were significantly
different from wildtypes. In A,‘ b’ indicates R6/2 mice at 6 weeks had a
longer latency to fall than R6/2 mice at 8 and 10 weeks of age and ‘c’
denotes a significant decrease in R6/2 mice at 6, 8 and 10 weeks relative
to transgenic mice at 4 weeks old. In B,‘ b’ denotes an increase in body
weight between R6/2 mice at 4 weeks of age and R6/2 mice at 6, 8 and
10 weeks. All p-values#0.035 by three-way ANOVA and simple effects
analysis.
doi:10.1371/journal.pone.0028409.g004
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significant decreases in soluble protein level from 4 weeks of age on
(i.e. 4 weeks.6 weeks.8 weeks.10 weeks) (p-values#0.018)
(Figure 7). In addition, time-resolved FRET (TR-FRET) analysis
revealed the presence of aggregates in 4 week old 110Q
transgenics, prior to phenotypic onset. Although aggregated
protein measures from 4 and 6 week old transgenic mice
showed no significant increase, levels of aggregated transgene
protein rose at each age from 6 to 10 weeks (i.e. 6 weeks,8
weeks,10 weeks) (p-values#0.001).
Immunohistochemistry (IHC)
To further confirm the presence of aggregates prior to
phenotypic onset as well determine the intracellular localization
of aggregates present, the anti-huntingtin antibody, EM48, was
used in IHC experiments to look at aggregate load in brain tissue
sections of 110Q R6/2 mice.
EM48 staining of brain sections from R6/2 mice at 4 and 10
weeks of age again confirmed the aggregate increases reported in
the TR-FRET experiments (Figure 8) and showed that
aggregates are present prior to explicit phenotype onset (as
measured by behavioral testing) in 110Q mice. Although the
increase in aggregation from 4 to 10 weeks in the 110Q mice, as
seen by IHC is not visually explicit, nonetheless differences are
observed. Although not quantified, the EM48-stained sections
reveal a clear increase in aggregated HTT protein from 4 to 10
weeks of age in both the cortex and striatum of 110Q mice. In
addition tissue samples from 4 week old 110Q mice exhibit few
examples of small, circular intranuclear inclusions characteristic
of 110Q R6/2 mice and such inclusions are readily identified in
the nuclei of neurons of 10 week old 110Q mice. Furthermore
EM48 staining appears to darken in intensity between 4 and 10
weeks of age suggesting increased aggregate load. Similar
patterns of staining intensity have been observed across age in
YAC128 mice [8].
Discussion
This study reports the generation of congenic R6/2 mice carrying
110 CAG expansion mutation exhibiting minimal instability. By
employing a breeding scheme utilizing speed congenics, we illustrate
the relative rapidity with which HD-model mice can be backcrossed
onto a pure genetic background, allowing for behavioral testing as
well as the exploration of differences in HD-like phenotypes on
multiple genetic backgrounds and the identification of the potential
for modifiers of HD symptoms. Importantly, the discovery of a novel
CAG repeat with relative stability while backcrossing our R6/2
colony provided a unique opportunity to study the phenotypes
associated with a newlineofR6/2 that does not undergoprogressive
intergenerational expansions and is presented on a congenic
background. It is important to note that our intergenerational
repeat length stabilitydata are based on the analysis of tissue samples
fromsingle earpunches inmicefrom eachgeneration; withinsubject
somatic repeat stability was not measured in this study. However,
because somatic tissue stability has been shown to be separable from
traditional intergenerational stability measurements [19], experi-
ments to assess the somatic stability in striatal tissue are currently
underway to further characterize the apparent repeat length stability
of the 110Q line. At the present time, we do not know why the
present 110Q line displays minimal instability, but we speculate that
there may be an unidentified mutation within the transgene, or the
introduction of an unknown mutation in a modifier locus near the
insertion site. Furthermore, although the exact mechanism resulting
in expansion of CAG repeats is unknown, many studies have clearly
shown a role for mismatch repair proteins in trinucleotide instability
[26,27,28,29,30,31,32,33,34], suggesting changes in the expression
of a protein in the mismatch repair pathway may also explain the
relative stability of the 110Q mice.
In the present study, data from congenic 110Q mice exhibiting
minimal CAG instability exhibit impairments relative to wildtype
mice frequently beginning between 6 and 8 weeks of age. Reduced
activity and exploration in multiple measures of the open field
Table 2. F-values for interactions found in behavioral tests are shown and simple effects analysis of specific age comparisons
within each genotype.
Assay Interaction
4 wks vs.
6 wks
4 wks vs.
8 wks
4 wks vs.
10 wks
6 wks vs.
8 wks
6 wks vs.
10 wks
8 wks vs.
10 wks
Total Distance (genotype6age) F(1,203)=16.256,
p,0.001
Wt p=0.573
Tg p=0.215
Wt p=0.002
Tg p=0.007
Wt p=0.002
Tg p,0.001
Wt p=0.007
Tg p,0.001
Wt p=0.008
Tg p,0.001
Wt p=0.797
Tg p=0.172
Vertical Activity (genotype6age) F(1,203)=29.819,
p,0.001
Wt p=0.022
Tg p=0.854
Wt p,0.001
Tg p=0.001
Wt p,0.001
Tg p,0.001
Wt p,0.001
Tg p=0.001
Wt p,0.001
Tg p=0.001
Wt p=0.278
Tg p=0.614
Rotarod (genotype6age) F(3,204)=7.002,
p,0.001
Wt p=0.132
Tg p=0.039
Wt p=0.018
Tg p=0.002
Wt p=0.085
Tg p,0.001
Wt p=0.326
Tg p=0.238
Wt p=0.813
Tg p=0.039
Wt p=0.415
Tg p=0.337
Body Weight (genotype6age) F(1,204)=161.310,
p,0.001
Wt p,0.001
Tg p,0.001
Wt p,0.001
Tg p,0.001
Wt p,0.001
Tg p,0.001
Wt p,0.001
Tg p=0.215
Wt p,0.001
Tg p=0.353
Wt p=0.035
Tg p=0.827
Prepulse Inhibition Females
Acoustic Startle (genotype6age6gender) F(1,203)=3.273,
p=0.022
Wt p=0.467
Tg p=0.049
Wt p=0.263
Tg p=0.040
Wt p=0.381
Tg p=0.009
Wt p=0.602
Tg p=0.901
Wt p=0.860
Tg p=0.455
Wt p=0.716
Tg p=0.539
Males
Wt p=0.004
Tg p=0.161
Wt p,0.001
Tg p,0.001
Wt p,0.001
Tg p=0.003
Wt p,0.001
Tg p,0.001
Wt p,0.001
Tg p=0.060
Wt p=0.460
Tg p=0.226
Average PPI (genotype6age) F(3,203)=4.569,
p=0.004
Wt p=0.674
Tg p=0.955
Wt p=0.636
Tg p=0.914
Wt p=0.199
Tg p=0.009
Wt p=0.936
Tg p=0.864
Wt p=0.081
Tg p=0.008
Wt p=0.087
Tg p=0.006
Passive Avoidance Days 2 &3
(genotype6age)
F(3,192)=3.666,
p=0.013
Wt p=0.011
Tg p=0.311
Wt p=0.006
Tg p=0.583
Wt p,0.001
Tg p=0.908
Wt p=0. 438
Tg p=0.125
Wt p=0.060
Tg p=0.394
Wt p=0.470
Tg p=0.521
doi:10.1371/journal.pone.0028409.t002
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weeks of age. This result was further confirmed in 6 week old mice
when tested in the rotarod assay. Overall, male and female
transgenic mice performed similarly to male and female wildtype
mice as has been observed in several studies of R6/2 mice
[6,9,35,36]. However, gender differences in transgenic phenotypes
were observed in the phenotypic development of sensorimotor
gating impairments. Deficits in sensorimotor gating have been
found among HD patients [37] and have been identified
previously in R6/2 mice as well as other animal models of HD
[6,38,39,40,41,42]. In our study, female R6/2 mice exhibited
decreased startle responses at 4 weeks of age while male 110Q R6/
2 mice were found to be impaired in startle amplitude at every age
as well as in inhibition of the startle at 10 weeks old. Although we
identified PPI phenotypes primarily in male transgenic mice,
previous studies of R6/2 mice have reported acoustic startle and
PPI impairments in both genders [6,41]. The discrepancy between
our data, which showed phenotypes primarily in male transgenic
mice, and those of Carter et al. [41] and Menalled et al. [6], which
identified phenotypes in both genders, may be explained by
differences in ages tested, repeat length, or genetic background,
which is known to influence many aspects of behavior [6,8].
Several studies have shown learning and memory and
psychiatric-related phenotypes in R6/2 mice as well as other
mouse models of HD including spatial learning, alternation, visual
and reversal learning, social interactions and learning and
inhibition [35,36,38,40,43,44]. In many studies, the results are
confounded by motor impairments characteristic of the HD
models [5,40,41,42] and very few have successfully separated
motor deficits from learning or cognitive impairments [36]. In the
present study we have provided evidence in support of a non-
motor, striatal-based decreased inhibition phenotype in 110Q R6/
2 mice. Because of the nature of the behavioral requirements in
the passive avoidance learning and memory task, we were able to
show that despite having motor impairments, the R6/2 mice have
impaired performance. More specifically, since the motor
impairments in R6/2 mice result in reduced activity as seen in
their decreased latency on the training day, we expected a longer
latency to enter the dark due to the reduced activity on the test
days. Yet the data from test days 2 and 3 clearly show that
transgenic R6/2 mice entered the dark significantly faster than
wildtype mice.
Therefore, despite having motor impairments, the R6/2 mice
can engage in the necessary behaviors required to perform the
passive avoidance test, and thus the ‘impaired’ performance can be
dissociated from a motor impairment. Furthermore, because the
transgenic mice improved significantly across days in the passive
avoidance task (although performance scores were still significantly
Figure 5. Sensorimotor gating in B6 R6/2 mice across 4 ages. (A) Acoustic startle response measurements in male mice. Male R6/2 mice show
reduced startle phenotypes at every age tested. The startle response in male R6/2 mice increased significantly from 4 to 6 and 6 to 8 weeks of age,
but always remained below wildtype levels. (B) Acoustic startle response in female mice. Female R6/2 mice exhibit a significant reduction in startle
response only at 4 weeks of age. A significant increase in startle was observed from 4 to 6 weeks in R6/2 females and at all later ages female R6/2
mice showed similar startle responses to wildtype mice. (C) Average percent PPI of wildtype and R6/2 mice (combined genders). Average PPI was
normal in R6/2 mice at early ages but decreased inhibition was observed at 10 weeks of age. Follow-up analyses revealed that the inhibition deficits
were present only in male R6/2 mice. (D) Percent PPI in male and female mice. Overall, male R6/2 mice show decreased inhibition compared to
wildtype mice while female R6/2 mice performed comparably to controls. In all panels, ‘a’ reflects a decreased performance in R6/2 mice compared to
wildtypes. All p-values#0.012 by three-way ANOVA and simple effects analysis.
doi:10.1371/journal.pone.0028409.g005
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observed are not due to a deficiency in learning or memory per se,
but is more likely that the decreased latency to enter the dark is the
result of problems with inhibition. Our findings contrast to
previous findings in which R6/2 mice were found to have a longer
latency to enter the dark chamber an inhibitory avoidance task
[43]. However, the current study is not the first study to show
reduced inhibition, stimulus-response deficits or neuronal dys-
function in the striatum R6/2 mice [36,43,45]. For example
impairments have been reported in multiple stimulus-response
tests including the active avoidance task in which mice must learn
to respond to a conditioned stimulus to escape shock [43] and a
two-choice water box in which mice are required to swim toward a
light to find the escape platform [36]. In addition, Kung et al. [45]
illustrate molecular changes in the R6/2 striatum with evidence of
impairments in dopamine-dependent neuronal plasticity, provid-
ing evidence for striatal dysfunction and a possible mechanism to
explain the striatum-based motor and cognitive impairments
observed in R6/2 mice. Further studies will be necessary to better
understand the nature of the passive avoidance impairment and to
more specifically address the possible dissociation between
impaired memory and response inhibition.
Furthermore our data suggest that some changes in cognitive or
psychiatric-related phenotypes including anxiety in the open field,
prepulse inhibition and passive avoidance learning do not precede
motor impairments in 110Q R6/2 animals (in which motor
impairments occur as early as 4 weeks old). In another study,
Lione et al. [36] successfully dissociated cognitive impairments
from motor deficits using the Morris water maze. In the Lione
study, the decline in performance of transgenic mice in spatial
learning occurred before the onset of motor phenotypes. The
differential results, with regard to cognitive or psychiatric features
occurring prior to motor phenotypes, between our study and
Lione et al. [36] may reflect different types of learning,
differentially affected brain regions (i.e. the striatum or the
hippocampus), or be due to the differences in genetic background
or repeat length, although the latter was not reported.
In addition to characterizing the behavioral phenotypes of
110Q congenic R6/2 mice with minimal mutation instability, the
findings of the present study expand the current knowledge of R6/
2 mice by elucidating several molecular changes associated with
disease onset and progression in the R6/2 model. Among the
molecular phenotypes associated with disease, changes in the levels
of soluble and insoluble mutant HTT protein (as measured by TR-
FRET) were found. We observed a decrease in soluble protein
with disease onset and a concurrent increase in aggregated protein
levels. However, we found no differences in transgene transcript
expression in R6/2 mice; that is, transcript expression levels were
stable throughout disease progression and were not associated with
disease onset. This suggests that protein state changes, and not
changes in transcript expression, may be associated with disease
onset and progression.
Figure 6. Passive avoidance learning across 4 ages. (A) Latency
to enter the dark on test days 2 and 3 of passive avoidance test. (B)
Latency to enter the dark across test days combined across ages. For
wildtype and R6/2 mice, latency to enter the dark increased significantly
with each training day. R6/2 mice took longer to enter the dark on day
1, but exhibited significantly shorter latencies on days 2 and 3. In panel
A,‘ a’ represents a decreased latency to enter the dark in R6/2 mice
compared to wildtypes. All p-values#0.018 by three-way ANOVA and
simple effects analysis.
doi:10.1371/journal.pone.0028409.g006
Table 3. Transcript expression across age in 110Q mice.
Age Gene Relative Expression (normalized to 110Q at 4 weeks) SEM
1 p-value
2
6 weeks HTT 0.836 0.584–1.289 0.218
Hdh 1.124 0.805–1.465 0.314
8 weeks HTT 0.846 06.31–1.180 0.205
Hdh 0.972 0.794–1.162 0.739
10 weeks HTT 0.881 0.606–1.303 0.341
Hdh 0.926 0.707–1.237 0.452
1SEM represents the range of standard error of the means for statistical randomization tests.
2p-values.0.05, n.s.
doi:10.1371/journal.pone.0028409.t003
Phenotypes of a Congenic and Stable R6/2 Line
PLoS ONE | www.plosone.org 8 December 2011 | Volume 6 | Issue 12 | e28409At later ages (i.e. 8–10 weeks), data from the present study show
that the congenic B6 110Q mice that show intergenerational
stability parallel many of the phenotypes commonly observed in
R6/2 mice on a mixed genetic background that do not show
intergenerational stability including reduced body weight, motor
impairments and decreased exploration [5,6,9,35,36,41]. Al-
though 110Q R6/2 mice were largely healthy and perform
comparably to wildtype littermates at 4 weeks of age, impairments
in startle and sensorimotor gating were observed at this young age
suggesting that some aspects of disease occur early in development
in R6/2 mice. In addition, the present study provides evidence for
striatal-dependent inhibition impairments in a learning and
memory assay [22,23] in B6 110Q R6/2 mice that are not
present prior to the onset of HD-like motor symptoms. Finally, we
show a progression of disease onset in B6 110Q mice across age
both behaviorally and in molecular changes in protein state and
aggregation of the mutant transgene product. While previous
studies have shown similarly progressive phenotypes in both the
R6/2 and other HD mouse models [8,35,36,41,42,46], no
concurrent progressive molecular phenotypes have been published
on R6/2 mice. Our results, however, are neither surprising nor
unique to the R6/2 model. YAC128 mice have been reported to
exhibit correlations between behavioral disease progression
accompany progressive changes at the molecular level including
susceptibility to excitotoxicity and cortico-striatal activity [24,25].
Taken together, the results of our study and those observed in
YAC128 mice suggest that insights into disease onset, mechanism,
and progression can be gained through understanding the
molecular changes that occur in concert with motor and cognitive
symptoms.
Materials and Methods
Ethics Statement
Animal care and testing was approved by the Baylor College of
Medicine Animal Care and Use Committee under protocol
Figure 8. EM48 staining for aggregated mutant HTT appears to increase in amount and intensity with increasing age and disease
progression. In 4 week old B6 110Q R6/2 mice, very few small, circular intranuclear inclusions characteristic of 110Q R6/2 mice can be identified.
However, by 10 weeks of age such inclusions are readily observed neuronal nuclei. Intensity of EM48 staining appears increase from 4 and 10 weeks
of age, further suggesting an increase in aggregate load.
doi:10.1371/journal.pone.0028409.g008
Figure 7. Mutant HTT protein progresses from soluble to
aggregated forms with increasing age and disease progres-
sion. Relative levels of soluble and aggregated transgene protein
across four ages. Soluble protein levels significantly decrease at every
age. Aggregated protein levels increase at each age from 6 to 10 weeks.
All p-values#0.018 by one-way ANOVA.
doi:10.1371/journal.pone.0028409.g007
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guidelines.
Animals
Male R62 mice carrying a transgene with a 110-polyglutamine
(110Q) tract (Jackson Laboratory, Bar Harbor, ME) were
originally obtained on a mixed CBA6C57BL/6J background.
Using speed congenics mice were backcrossed onto C57BL/6J
(B6) background based on a 96 short sequence length polymor-
phisms (SSLPs) marker panel until congenic (details provided in
Marker-Assisted Speed Congenics methods section). After obtain-
ing a fully B6 congenic 110Q R6/2 line, female B6 110Q R6/2
mice underwent ovarian transfer (OT) from a transgenic to a
wildtype female at Jackson Laboratory. The female OT R6/2
mice were then returned to our lab at Baylor College of Medicine
and were bred to male B6 mice in our colony. Weaned progeny
were housed 2–5 animals per cage with a 12-hour light cycle. Food
and water were provided ad libitum.
Marker-Assisted Speed Congenics
In order to efficiently create a congenic B6 R62 line, a marker-
assisted speed congenics selective breeding strategy was used
[47,48]. A 96 SSLP marker panel was chosen using Jackson
Laboratories online genes and markers database (http://www.
informatics.jax.org/genes.shtml). Approximately 4–5 markers
were chosen on each chromosome with no more than 20 cM
between markers to enhance detection of recombination events.
PCRs assaying all 96 markers were performed for each mouse, and
PCR products were analyzed on poly-acrylamide gels. Male 110Q
mice from each generation containing the highest percentage of
homozygous B6 markers were used for breeding. Mice were
backcrossed until all 96-markers analyzed were found to be
homozygous B6.
Genotyping and CAG Repeat Length
All mice were genotyped using PCR amplification of DNA
extracted from tails clippings. Transgenic animals were identified
using primers (59-GCCGCTCAGGTTCTGCTTT-39 and 59-
AAGGCCTTCATCAGCTTTTCC-39) to amplify the 59 region
of the transgene, yielding a 150 base-pair product. Tissue obtained
from ear clips of all mice were sent to Laragen, Inc. (Los Angeles,
CA) to measure the polyglutamine expansion by Genescan and
sequencing modes using an ABI 377 sequencer. Mice used in this
study had repeats ranging from 107–115 CAG.
Insertion Site Characterization
Genomic sequences flanking the transgene integration site were
identified using the PCR-based Genomewalker Universal Kit
(Clontech Laboratories, Inc., Mountain View, CA) according to
the manufacturer’s instructions. In summary, restriction enzyme
digestions were performed using purified high molecular weight
genomic DNA isolated from R6/2 and wild-type mice. Kit supplied
GenomeWalker Adaptor oligos were ligated to the genomic DNA
fragmentsand primary PCRamplification wascarried using a gene-
specific primer (GSP1; 59-AGGACAAGGGAAGACCCAAGT-39)
and an Adaptor-specific primer (AP1; see manufacturer protocol). A
second, nested PCR amplification was carried out using diluted
primary PCR product as template and a second gene-specific
(GSP2; 59-TCTGGGTTGCTGGGTCACTCT-39) and Adaptor-
specific primer (AP2; see manufacturer protocol) pair. The final
amplification products were resolved on an agarose gel and visible
band(s) were isolated, purified, and then sequenced. Publicly
available homology search programs were then utilized to identify
the chromosomal region flanking the construct (http://genome.
ucsc.edu/cgi-bin/hgBlat). The transgene insertion site was further
confirmed by follow-up targeted PCR using primers 59GCAAG-
CAAGGGGAGGAAAAG-39 and 59-AGGCCCATGCGGAAA-
GGAT-39.
Behavioral Testing
Male and female 110Q mice were tested in a variety of
behaviors in the following order: (1) open-field activity, (2) rotarod,
(3) prepulse inhibition and (4) passive avoidance. Mice were used
in one test per day and each test was performed with no less than
one and no more than three days in between. In general, testing
was completed over a ten-day period. Mice were given a 30-
minute rest period after being moved to testing rooms each day.
All behavioral experiments were carried out between 8 AM and 1
PM. N for each age group tested were as follows: 4 week n=13 Tg
females, n=14 Tg males, n=10 Wt females, n=17 Wt males; 6
week n=14 Tg females, n=19 Tg males, n=14 Wt females,
n=14 Wt males; 8 week n=14 Tg females, n=17 Wt males, n=8
Wt females, n=15 Wt males; 10 week n=13 Tg females, n=10
Tg males, n=13 Wt females, n=14 Wt males. Naı ¨ve mice were
used in each age group. The average repeat length for mice used
in behavioral experiments is 112.4861.082 SEM.
Open Field Activity. Mice were transferred from a cage to
the center of a clear Plexiglas arena (40640630 cm). The
duration of the test was 30 minutes, during which time mice
were allowed to explore freely. Overhead lighting of 800 Lux was
placed above the open field chamber. White noise was provided at
55 dB during testing. The VersaMax Animal Activity Monitoring
System (AccuScan Instruments, Inc., Columbus, OH) was used to
monitor and record activity during the test. Activity was detected
by photobeam interruptions and measures including total distance
traveled, rearing and distance traveled in the center of the arena
(22.5 cm622.5 cm). The ratio of the center distance to the total
distance (center: total distance ratio) was also used as an index for
anxiety-like behaviors [20,21]. Beam breaks were computer
recorded over 2-minute intervals throughout the test period.
Data from the entire 30-minute test were analyzed.
Rotarod. Mice were placed on an UGO Basile Accelerating
Rota-Rod (Ugo Basile Company, Collegeville, PA) and the latency
to fall was recorded as a measure of motor skill and learning.
When an animal lost its balance but did not fall, and continued to
hold on to the rod, the time to the first full revolution was
recorded. Acceleration of the rod was from 4 to 40 rpm over a 5-
minute trial period. Mice were given four trials per day, with an
intertrial interval of 20–40 minutes, over two consecutive days.
The latency was averaged across all eight trials and analyzed. Prior
to testing on day one, the weight of each animal was measured and
recorded.
Prepulse Inhibition (PPI). Acoustic startle responses were
measured as to indicate sensorimotor gating performance using
the SR-Lab System (San Diego Instruments, San Diego, CA).
Mice were restricted inside holding tubes and presented with a
5 minute 70 dB background noise. In a single test session, six
blocks of trials were administered pseudo randomly. Each block
consisted of eight trial-types each trial-type was presented once
within each block; intertrial intervals ranged from 10–20 s.
‘‘Startle only’’ trials consisted of a 40 ms, 120 dB sound. In
three trials-types, prepulses consisting of 4, 8 or 12 dB above the
70 dB background were presented. Another three trials both
prepulse and acoustic startle stimulus. In the prepulse+startle trials,
prepulses were presented for 20 ms, 100 ms prior to the startle. In
the last trial-type only background noise was presented (for
measuring baseline movement). Response detection occurred for
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amplitude was used as the dependent variable and mice with
startle amplitude less than 100 were excluded from study results.
Percent prepulse inhibition of a startle response for each
prepulse level was calculated as follows: 1002[(startle response on
acoustic prepulse+startle stimulus trials/startle response alone
trials)6100]. The average PPI of all three prepulse intensities was
used as the measure for this experiment.
Passive Avoidance (PA). The three-day passive avoidance
test was conducted in a two-chamber box (42616621 cm) (Med
Associates, Saint Albans, VT, USA) divided by a white partition
containing a sliding door. One chamber is clear and brightly lit
(approximately 800 Lux) while the other is covered and kept dark.
Each day mice were placed in the light side of the box and the
partition was opened after 10 s. The latency to enter the dark side
was recorded. After a mouse entered the dark, the partition door
was closed and a 2 s, 0.5 mA foot shock was administered via a
grid floor; after 10 sec the mouse was returned to its home cage.
Approximately 24-hours later, mice were put back into the light
compartment with the partition open and the latency to enter the
dark was recorded with a maximum of 300 s. The protocol was
repeated approximately 24 hours later. After delivery of the shock,
vocalizations were noted, as an indication of the animal detected
the footshock stimulus. The latency to enter the dark on day three
was used as the measure of learning in this experiment.
Statistical Analyses for Behavior. Comparisons were made
between genotypes independently at each age. Data for OFA,
RROD, and PPI and PA day 1 were analyzed using three-way
(genotype6age6gender) Analysis of Variance (ANOVA). When
interactions were identified, further statistical analyses were
performed using simple-effects tests. Genotype6age analyses
revealed changes across age in some assays. The full details of
these progressive phenotypes are given in Table 2. Gender
differences were identified in weight and in PPI startle responses.
The gender6genotype interaction found in the weight data was
due to a greater mean difference between genders in wildtype
relative to R6/2 mice. Because this was not crucial to the
interpretation of the weight measures, the data from both genders
were collapsed for the data presented in the figure. Data from PPI
startle testing is shown separately for each gender. All other figures
represent combined data from both genders. Passive avoidance
results for days 2 and 3 were analyzed using a 3-way ANOVA with
repeated measures. All three days were analyzed independently for
each genotype using 1-way ANOVA with repeated measures to
look at performance changes across day.
Transgene Expression Analysis
Mice used in qPCR and TR-FRET experiments expressed a
mutant transgene with an average of 110 CAG (109.7360.248
SEM).
Tissue Collection. Upon completion of behavior studies,
mice were sacrificed by cervical dislocation and whole brain tissue
was immediately removed and stored in Ambion RNAlater tissue
collection RNA stabilization solution (Applied Biosystems/
Ambion, Austin, TX) at 4uC for 1–7 days after which tissue was
removed from excess RNAlater solution and stored at 280uC.
RNA Isolation and cDNA Synthesis. Total RNA was
isolated from mouse whole brain tissue and dounce
homogenized in Ambion TRI-Reagent. Phase separation of
homogenate was performed according to the manufacturer’s
protocol by addition of bromo-chloro-propane, incubation, and
centrifugation. The aqueous RNA phase was transferred, treated
with ethanol and column purified using the Ambion RiboPure Kit.
Genomic DNA was removed by treatment with Ambion
TurboDNAseI (Applied Biosystems/Ambion). Quality of RNA
was determined by nanodrop UV absorbance and with the Agilent
2100 Bioanalyzer. cDNA was generated using approximately 1 mg
of RNA and SuperScriptIII Reverse Transcriptase (Invitrogen,
Carlsbad, CA) and poly-T plus random hexamer primers.
Following cDNA synthesis, excess RNA was eliminated using
RNAseH enzyme (Invitrogen). cDNA was stored at 220uC.
geNorm Analysis and qPCR. To determine the reference
genes that are most stable in whole brain tissue across disease state
and age, total RNA from 4 each of 4, 6, 8 and 10 week old mice
were used to perform a geNorm analysis using seven commonly
used reference genes. For each gene, the primer and probe used
were developed as a Taqman gene expression assay (Applied
Biosystems, Foster City, CA) or a primer and double-dye
(Taqman-style) assay (PrimerDesign, Ltd., UK). Series dilutions
were run for each gene assay and efficiencies were calculated using
linear regression analysis. qPCR was performed and results were
analyzed using geNorm software (http://medgen.ugent.be/
,jvdesomp/genorm/). The three most stable reference genes
were selected for use in gene expression experiments.
Following geNorm analysis, gene expression experiments were
performed using reference genes CanX (Applied Biosystems,
Mm00626988_m1), Cyc1 (Applied Biosystems, Mm00470541_g1)
and Rpl13a (Applied Biosystems, Mm01612986_gH). The primers
used for amplifying the R62 transgene (HTT) were 59-
GCTGCACCGACCGTGAGT-39 and 59-CGCAGGCTGCAG-
GGTTAC-39 and a Taqman probe 6-FAM- CAGCTCCC-
TGTCCCGGCGG-TAMRA. Expression of the endogenous
mouse homolog, Hdh, was also measured using qPCR with primers
59-CTCAGAAGTGCAGGCCTTACCT-39 and 59-GATTCCT-
CCGGTCTTTTGCTT-39 and Taqman probe 6-FAM-TGA-
ATCTTCTTCCATGCCTGACCCGA-TAMRA. The efficiency
for each gene assay is as follows, HTT (78.2%), Hdh (99.8%), Canx
(94.97%), Cyc1 (96.7%), and Rpl13a (100.0%). 8 biological samples
each of 4, 6, 8 and 10-week old mice were used to measure
expression levels.
Statistical Analyses for Real Time RT-qPCR
REST 2009 Software program [49] was used to analyze data
from each experiment. Relative expression was calculated by
dividing the concentration of the gene of interest by the geometric
mean of the concentrations of reference genes used in each study
[50]. Simple statistical randomization tests were run with 10,000
iterations to determine expression ratios [51]. A hypothesis test
and bootstrapping methods were then used to determine
significance at the 95% confidence interval.
Protein Isolation and Time-Resolved FRET Analysis
Crude brain tissue homogenates from 4 wk Tg (n=9), 6 wk Tg
(n=7), 8 wk Tg (n=8), 10 wk (n=8) and 4 wk Wt (n=8) were
prepared by homogenization in 106 w/v lysis buffer (PBS+1%
TritonX100+Complete Protease Inhibitor (Roche, Switzerland))
by ultrasound pulses. 5 ml homogenate and 1 ml detection buffer
(50 mM NaH2PO4, 400 mM NaF, 0.1% BSA and 0.05%
Tween+antibody mix) were pipetted to low-volume wells of
opaque white 384 microtiter plates (Greiner, USA). The final
antibody amount per well was 1 ng 2B7-Tb+10 ng MW1-d2 or
1 ng 4C9-Tb+10 ng 4C9-Alexa488 for the quantification of
soluble mutant huntingtin and aggregated mutant Huntingtin
respectively. Plates were incubated for 1 h at room temperature
and samples were analyzed with an EnVision Reader (Perkin
Elmer, USA). The donor fluorophore terbium was excited at
320 nM. After a time delay of 100 ms, terbium, d2 and Alexa488
emission signals were read out for 200 ms at 620 nm, 665 nm and
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lysis buffer background.
For TR-FRET data, independent comparisons were made
across age for soluble and aggregated protein measures using one-
way ANOVA.
Immunohistochemistry
Mice were sacrificed by transcardial perfusion with 30–40 ml of
filtered-sterilized 0.2 M PBS, pH 7.2. Tissues were then fixed by
perfusion with 50 ml of cold 4% paraformaldehyde in 4% sucrose
PBS, pH 7.2. Whole brains were dissected and stored overnight in
the fix solution at 4uC. Within 24 hours post-perfusion, brain
samples were transferred to a filter-sterilized 0.2 M PBS
containing 0.01% sodium azide and kept at 4u. Brain samples
were paraffin embedded and coronally sectioned by Neuroscience
Associates, Inc. (Knoxville, TN) into 35-micron serial sections.
Immunolabeling with EM48 and thionine counterstain was
performed at 210-micron intervals. For this analysis, 4 wk Wt
n=4, 4 wk Tg n=6, 6 wk Tg n=5, 8 wk Tg n=5 and 10 wk Tg
n=5. For this study, the expansion size again showed minimal
instability with an average CAG number of 110 (110.3560.357
SEM).
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